Compare iShares MSCI ACWI ETF (ACWI) vs Novavax Inc (NVAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Novavax Inc — how do they compare? iShares MSCI ACWI ETF trades at $155.57, while Novavax Inc trades at $9.43 (market cap $1.56B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | NVAX | |
|---|---|---|
52-Week High | $159.97 | $11.19 |
52-Week Low | $128.32 | $6.22 |
Market Cap | — | $1.56B |
Sector | — | Health |
Enterprise Value | — | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.
Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
